Ten IPOs raised a combined $1.8 billion in August, joined by two direct listings. Activity slowed from July’s pace as the market entered its typical summer slowdown but was slightly above the month’s 10-year historical average (10 IPOs, $1.7B). Six...read more
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
Latigo Biotherapeutics, a Phase 3-ready biotech developing non-opioid therapies for acute and chronic pain, raised $346 million by offering 19.2 million shares at $18, the high end of the $16 to $18 range. The company had originally planned to offer 16 million...read more
Latigo Biotherapeutics, a Phase 3-ready biotech developing non-opioid, oral therapies for acute and chronic pain, announced terms for its IPO on Monday. The Thousand Oaks, CA-based company plans to raise $272 million by offering 16 million shares at a price...read more
Renaissance Capital’s August IPO Market Update
Ten IPOs raised a combined $1.8 billion in August, joined by two direct listings. Activity slowed from July’s pace as the market entered its typical summer slowdown but was slightly above the month’s 10-year historical average (10 IPOs, $1.7B). Six...read more
US IPO Weekly Recap: August kicks off with flurry of biotech IPOs
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
Latigo Biotherapeutics prices upsized IPO at $18, the high end of the range
Latigo Biotherapeutics, a Phase 3-ready biotech developing non-opioid therapies for acute and chronic pain, raised $346 million by offering 19.2 million shares at $18, the high end of the $16 to $18 range. The company had originally planned to offer 16 million...read more
Pain relief biotech Latigo Biotherapeutics sets terms for $272 million IPO
Latigo Biotherapeutics, a Phase 3-ready biotech developing non-opioid, oral therapies for acute and chronic pain, announced terms for its IPO on Monday. The Thousand Oaks, CA-based company plans to raise $272 million by offering 16 million shares at a price...read more